表紙
市場調査レポート

ワクチンの世界市場:2021年までの予測 - 肺炎球菌・インフルエンザ・HPV・肝炎・ロタウイルス・DTP・ポリオ・MMR

Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021

発行 MarketsandMarkets 商品コード 278597
出版日 ページ情報 英文 159 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
ワクチンの世界市場:2021年までの予測 - 肺炎球菌・インフルエンザ・HPV・肝炎・ロタウイルス・DTP・ポリオ・MMR Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021
出版日: 2016年08月09日 ページ情報: 英文 159 Pages
概要

2016年の322億4000万米ドルから8.3%のCAGR (複合年間成長率) で成長し、2019年までに480億3000万米ドルに達すると予測されています。同市場の主要な成長促進因子は、各種疾患の患者数の多さや、政府・民間からのワクチン開発への巨額の援助、予防接種計画への関心増加などがあります。更に、研究開発 (R&D) 費用の増額や、民間企業による新規ワクチン開発も、市場の更なる成長に貢献しています。

当レポートでは、ワクチンの世界市場について調査し、市場の概要、技術・種類・適応症・エンドユーザーおよび地域別の市場分析と予測を提供しており、競合情勢や主要企業のプロファイルをまとめ、お届け致します。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 ワクチンの世界市場:概要

  • イントロダクション
  • 市場区分
  • 市場ダイナミクス
    • 促進要因
      • 各種疾患の有病者数の多さ
      • 政府・民間からのワクチン開発への資金提供
      • 各企業の投資増額
      • 予防接種プログラムに対する政府の関心
    • 抑制要因
      • 巨額の資本投資
      • 厳格な規制
    • 市場機会
      • 新興国市場での急速な成長の見通し
      • 治療用ワクチン
      • アジュバントワクチン
    • 課題
      • ワクチンの入手可能性の低さ
      • ワクチンの価格設定
    • 目下の課題
      • ワクチンの失敗事例
  • 投資分析
  • 世界各地の規制情勢
  • 特許分析
  • 主なパイプライン製品

第6章 ワクチンの世界市場:技術別

  • イントロダクション
  • 結合型ワクチン
  • 不活性化・サブユニットワクチン
  • 弱毒化生ワクチン
  • トキソイドワクチン
  • 組み換えワクチン

第7章 ワクチンの世界市場:種類別

  • イントロダクション
  • 単価ワクチン
  • 多価ワクチン

第8章 ワクチンの世界市場:適応症別

  • イントロダクション
  • 肺炎球菌性疾患
  • DTP (三種混合ワクチン)
  • インフルエンザ
  • ヒトパピローマウイルス
  • 髄膜炎菌性疾患
  • ポリオ (小児まひ)
  • ロタウィルス
  • 肝炎
  • MMR (新三種混合ワクチン)
  • 水痘
  • その他

第9章 ワクチンの世界市場:エンドユーザー別

  • イントロダクション
  • 小児
  • 成人

第10章 ワクチンの世界市場:地域別

  • イントロダクション
  • 北米 (米国、カナダ)
  • 欧州 (ドイツ、英国、フランス、イタリア、スペインなど)
  • アジア (日本、中国、インドなど)
  • 他の国々 (RoW)

第11章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合状況・動向
    • 協定・事業提携・事業協力
    • 規制の承認
    • 企業合併
    • 事業拡張
    • その他の動き

第12章 企業プロファイル

  • イントロダクション
  • PFIZER, INC.
  • GLAXOSMITHKLINE, PLC.
  • MERCK & CO., INC.
  • SANOFI PASTEUR
  • CSL LIMITED
  • EMERGENT BIOSOLUTIONS, INC.
  • JOHNSON & JOHNSON
  • MEDIMMUNE, LLC. (ASTRAZENECAの子会社)
  • アステラス製薬
  • SERUM INSTITUTE OF INDIA

第13章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 3113

The vaccines market is expected to reach USD 48.03 billion by 2021 from USD 32.24 billion in 2016 at a CAGR of 8.3%. The global vaccines market is segmented based on technology, type, disease indication, end-users, and regions. The conjugate vaccines segment is expected to register the highest growth rate in the vaccines market, by technology, during the forecast period. The high growth in this segment is attributed to the increasing company investments in development of new vaccines.

Based on end-users, the vaccines market is segmented into paediatrics and adults. The paediatrics segment is expected to account for the largest share of the market in 2016. Increasing prevalence of diseases in children and the rising number of awareness programs to promote vaccination will drive the growth of this market.

Geographically, the vaccines market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by rising government funding for vaccine research in the North American countries.

The major factors contributing to the growth of the vaccines market include high prevalence of diseases, rising government and nongovernment funding for vaccine development, and increasing focus on immunization programs. Furthermore, increasing R&D spending and new vaccine development activities by companies is another major factor driving the growth of this market.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.

The major players in this market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), and Serum Institute of India Pvt. Ltd. (India).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyses the vaccines market by technology, type, disease indication, end-users, and regions
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccines market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the vaccines market
  • Market Development: Comprehensive information about emerging markets. This report analyses the market for various vaccines across geographies
  • Market Diversification: Exhaustive information about new vaccines, untapped geographies, recent developments, and investments in the vaccines market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKET SEGMENTATION
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATION
  • 1.5. MARKET STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
  • 2.4. KEY DATA FROM SECONDARY SOURCES
  • 2.5. KEY DATA FROM PRIMARY SOURCES
  • 2.6. KEY INDUSTRY INSIGHTS
  • 2.7. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL VACCINES MARKET
  • 4.2. VACCINES MARKET, BY TYPE
  • 4.3. GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY END USER
  • 4.4. GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY
  • 4.5. GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET
  • 4.6. LIFECYCLE ANALYSIS, BY REGION, 2016

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. High prevalence of diseases
      • 5.3.1.2. Rising government and non-government funding for vaccine development
      • 5.3.1.3. Increasing investments by companies
      • 5.3.1.4. Increasing government focus on immunization programs
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Huge capital investments
      • 5.3.2.2. Stringent regulations
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. High growth prospects in emerging markets
      • 5.3.3.2. Therapeutic vaccines
      • 5.3.3.3. Adjuvant vaccines
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Inadequate access to vaccines
      • 5.3.4.2. Vaccine pricing
    • 5.3.5. BURNING ISSUES
      • 5.3.5.1. Vaccine failure
  • 5.4. INVESTMENT ANALYSIS
  • 5.5. REGULATORY LANDSCAPE
    • 5.5.1. NORTH AMERICA
    • 5.5.2. EUROPE
    • 5.5.3. ASIA
    • 5.5.4. ROW
  • 5.6. PATENT ANALYSIS
  • 5.7. KEY PIPELINE PRODUCTS

6. VACCINES MARKET, BY TECHNOLOGY

  • 6.1. INTRODUCTION
  • 6.2. CONJUGATE VACCINES
  • 6.3. INACTIVATED AND SUBUNIT VACCINES
  • 6.4. LIVE ATTENUATED VACCINES
  • 6.5. TOXOID VACCINES
  • 6.6. RECOMBINANT VACCINES

7. VACCINES MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. MONOVALENT VACCINES
  • 7.3. MULTIVALENT VACCINES

8. VACCINES MARKET, BY DISEASE INDICATION

  • 8.1. INTRODUCTION
  • 8.2. PNEUMOCOCCAL DISEASE
  • 8.3. DTP
  • 8.4. INFLUENZA
  • 8.5. HUMAN PAPILLOMA VIRUS
  • 8.6. MENINGOCOCCAL DISEASE
  • 8.7. POLIO
  • 8.8. ROTAVIRUS
  • 8.9. HEPATITIS
  • 8.10. MMR
  • 8.11. VARICELLA
  • 8.12. OTHERS

9. VACCINES MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PEDIATRICS
  • 9.3. ADULTS

10. VACCINES MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. U.K.
    • 10.3.3. FRANCE
    • 10.3.4. ITALY
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE (ROE)
  • 10.4. ASIA
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA (ROA)
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 11.3.2. REGULATORY APPROVALS
    • 11.3.3. ACQUISITIONS
    • 11.3.4. EXPANSIONS
    • 11.3.5. OTHER DEVELOPMENTS

12. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. INTRODUCTION
  • 12.2. PFIZER, INC.
  • 12.3. GLAXOSMITHKLINE, PLC.
  • 12.4. MERCK & CO., INC.
  • 12.5. SANOFI PASTEUR
  • 12.6. CSL LIMITED
  • 12.7. EMERGENT BIOSOLUTIONS, INC.
  • 12.8. JOHNSON & JOHNSON
  • 12.9. MEDIMMUNE, LLC. (A SUBSIDIARY OF ASTRAZENECA)
  • 12.10. ASTELLAS PHARMA INC.
  • 12.11. SERUM INSTITUTE OF INDIA

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INCIDENCE OF DISEASES, 2014-2015
  • TABLE 2: NIH FUNDING FOR VACCINE RESEARCH, 2012-2016 (USD MILLION)
  • TABLE 3: HIGH PREVALENCE OF DISEASES TO BOOST THE VACCINES MARKET
  • TABLE 4: HUGE CAPITAL INVESTMENTS TO LIMIT THE MARKET GROWTH OF VACCINES
  • TABLE 5: HIGH GROWTH POTENTIAL IN EMERGING COUNTRIES TO BOOST THE MARKET FOR VACCINES
  • TABLE 6: IMMUNIZATION COVERAGE, BY DISEASE, 2014
  • TABLE 7: INADEQUATE ACCESS TO VACCINES A MAJOR CHALLENGE IN THE MARKET
  • TABLE 8: REGULATORY AUTHORITIES IN EUROPE
  • TABLE 9: REGULATORY AUTHORITIES IN ASIA
  • TABLE 10: KEY PIPELINE VACCINES
  • TABLE 11: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 12: CONJUGATE VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES
  • TABLE 14: INACTIVATED AND SUBUNIT VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 15: LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: TOXOID VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: RECOMBINANT VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 19: MONOVALENT VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: EXAMPLES OF MULTIVALENT VACCINES
  • TABLE 21: MULTIVALENT VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD MILLION)
  • TABLE 23: LIST OF PNEUMOCOCCAL VACCINES
  • TABLE 24: VACCINES MARKET SIZE FOR PNEUMOCOCCAL DISEASE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: LIST OF DTP VACCINES
  • TABLE 26: VACCINES MARKET SIZE FOR DTP, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: LIST OF INFLUENZA VACCINES
  • TABLE 28: VACCINES MARKET SIZE FOR INFLUENZA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: LIST OF HPV VACCINES
  • TABLE 30: VACCINES MARKET FOR HPV, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 31: LIST OF MENINGOCOCCAL VACCINES
  • TABLE 32: VACCINES MARKET SIZE FOR MENINGOCOCCAL DISEASE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 33: LIST OF POLIO VACCINES
  • TABLE 34: POLIO MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 35: LIST OF ROTAVIRUS VACCINES
  • TABLE 36: VACCINES MARKET SIZE FOR ROTAVIRUS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 37: LIST OF HEPATITIS VACCINES
  • TABLE 38: VACCINES MARKET SIZE FOR HEPATITIS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 39: LIST OF MMR VACCINES
  • TABLE 40: VACCINES MARKET SIZE FOR MMR, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 41: LIST OF VARICELLA VACCINES
  • TABLE 42: VACCINES MARKET SIZE FOR VARICELLA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 43: LIST OF OTHER VACCINES
  • TABLE 44: VACCINES MARKET SIZE FOR OTHER DISEASES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 45: VACCINES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 46: VACCINES MARKET SIZE FOR PEDIATRICS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 47: NORTH AMERICA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 48: VACCINES MARKET SIZE FOR ADULTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 49: NORTH AMERICA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 50: VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 51: NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 52: NORTH AMERICA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 53: NORTH AMERICA: VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 54: NORTH AMERICA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD MILLION)
  • TABLE 55: NORTH AMERICA: VACCINES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 56: U.S.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 57: U.S.: VACCINES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 58: CANADA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 59: CANADA: VACCINES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 60: EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 61: EUROPE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 62: EUROPE: VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 63: EUROPE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD MILLION)
  • TABLE 64: EUROPE: VACCINES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 65: GERMANY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 66: U.K.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 67: FRANCE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 68: ITALY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 69: SPAIN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 70: ROE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 71: ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 & 2014 (USD)
  • TABLE 72: ASIA: VACCINES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 73: ASIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 74: ASIA: VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 75: ASIA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD MILLION)
  • TABLE 76: ASIA: VACCINES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 77: JAPAN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 78: CHINA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 79: INDIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 80: ROA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 81: ROW: VACCINES MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 82: ROW: VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 83: ROW: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2014-2021 (USD MILLION)
  • TABLE 84: ROW: VACCINES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 85: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2013-2016
  • TABLE 86: REGULATORY APPROVALS, 2013-2016
  • TABLE 87: ACQUISITIONS, 2013-2016
  • TABLE 88: EXPANSIONS, 2013-2016
  • TABLE 89: OTHER DEVELOPMENTS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: VACCINES MARKET SEGMENTATION
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: TOP-DOWN APPROACH
  • FIGURE 4: BOTTOM-UP APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: VACCINES MARKET SIZE, BY TECHNOLOGY, 2016 VS. 2021 (USD MILLION)
  • FIGURE 8: GLOBAL VACCINES MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 9: GLOBAL VACCINES MARKET, BY DISEASE INDICATION, 2016
  • FIGURE 10: GLOBAL VACCINES MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
  • FIGURE 11: GLOBAL VACCINES MARKET, BY REGION, 2016 (USD MILLION)
  • FIGURE 12: HIGH PREVALENCE OF DISEASES AND RISING GOVERNMENT & NON-GOVERNMENT FUNDING FOR VACCINE DEVELOPMENT-PRIMARY GROWTH DRIVERS FOR THE GLOBAL VACCINES MARKET
  • FIGURE 13: MONOVALENT VACCINES SEGMENT TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
  • FIGURE 14: PEDIATRICS SEGMENT TO DOMINATE THE VACCINES MARKET IN 2021
  • FIGURE 15: CONJUGATE VACCINES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 16: U.S. TO DOMINATE THE VACCINES MARKET IN 2016
  • FIGURE 17: ASIA TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINES MARKET DURING THE FORECAST PERIOD
  • FIGURE 18: VACCINE MARKET SEGMENTATION
  • FIGURE 19: VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 20: INVESTORS PLAY AN IMPORTANT ROLE IN THE VACCINES MARKET
  • FIGURE 21: VACCINE FUNDING, BY INVESTOR, 2014
  • FIGURE 22: GAVI VACCINE FUNDING, BY TYPE OF INVESTOR, 2014
  • FIGURE 23: HIV PREVENTIVE VACCINES R&D FUNDING, BY INVESTOR, 2014
  • FIGURE 24: REGULATORY APPROVAL PROCESS FOR VACCINES
  • FIGURE 25: NORTH AMERICA ACCOUNTED FOR THE LARGEST NUMBER OF PATENT FILINGS IN 2012
  • FIGURE 26: THE U.S. ACCOUNTED FOR LARGEST NUMBER OF PATENT FILINGS ACROSS THE GLOBE (2012)
  • FIGURE 27: CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINES MARKET DURING THE FORECAST PERIOD
  • FIGURE 28: ASIAN MARKET FOR LIVE ATTENUATED VACCINES TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 29: NORTH AMERICA IS EXPECTED TO DOMINATE THE RECOMBINANT VACCINES MARKET DURING THE FORECAST PERIOD
  • FIGURE 30: MONOVALENT VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET FROM 2016 TO 2021
  • FIGURE 31: NORTH AMERICA IS EXPECTED TO DOMINATE THE MULTIVALENT VACCINES MARKET DURING THE FORECAST PERIOD
  • FIGURE 32: PNEUMOCOCCAL DISEASE SEGMENT EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 33: ASIA IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE INFLUENZA DISEASE SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 34: NORTH AMERICA TO DOMINATE THE MENINGOCOCCAL DISEASE MARKET DURING THE FORECAST PERIOD
  • FIGURE 35: ASIAN MARKET FOR HEPATITIS VACCINES TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 36: THE PEDIATRICS END-USER SEGMENT DOMINATES THE GLOBAL VACCINES MARKET IN 2016
  • FIGURE 37: ASIA TO WITNESS THE HIGHEST GROWTH RATE IN THE VACCINES MARKET FOR ADULTS DURING THE FORECAST PERIOD
  • FIGURE 38: GEOGRAPHIC SNAPSHOT (2016): EMERGING MARKETS TO OFFER GROWTH OPPORTUNITIES
  • FIGURE 39: GEOGRAPHIC BENCHMARKING FOR VACCINES TECHNOLOGY MARKET
  • FIGURE 40: NORTH AMERICA: VACCINES MARKET SNAPSHOT, 2016
  • FIGURE 41: EUROPE: VACCINES MARKET SNAPSHOT, 2016
  • FIGURE 42: ASIA: VACCINES MARKET SNAPSHOT, 2016
  • FIGURE 43: ORGANIC AND INORGANIC GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS FROM 2013 TO 2016
  • FIGURE 44: GLOBAL VACCINES MARKET SHARE, BY KEY PLAYER, 2015
  • FIGURE 45: BATTLE FOR MARKET SHARE: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS WERE THE PREFERRED STRATEGIES BY MARKET PLAYERS
  • FIGURE 46: PRODUCT BENCHMARKING FOR TOP 4 MARKET PLAYERS
  • FIGURE 47: PFIZER, INC.: COMPANY SNAPSHOT
  • FIGURE 48: GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT
  • FIGURE 49: MERCK & CO., INC.: COMPANY SNAPSHOT
  • FIGURE 50: SANOFI PASTEUR: COMPANY SNAPSHOT
  • FIGURE 51: CSL LIMITED: COMPANY SNAPSHOT
  • FIGURE 52: EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
  • FIGURE 53: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 54: ASTRAZENECA : COMPANY SNAPSHOT
  • FIGURE 55: ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
Back to Top